Secureworks Unveils Secureworks Taegis™, XDR Advancements, and MSSP Partner Initiative to Strengthen Cybersecurity Community
Secureworks marshals software, brand and channel to protect enterprises and fight adversaries at scale Secureworks…
Year: 2021
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and…
Update on vaccine production at BioNTech’s manufacturing site in Marburg
MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) – We started the manufacturing process at the…
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate…
PCI Biotech – release of the RNA Therapeutics Virtual Conference presentation
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing…
Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) — Biophytis (Euronext Growth Paris: ALBPS)…
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) — Biophytis (Euronext Growth Paris: ALBPS)…
Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)
Clinical proof of concept achieved for derazantinib monotherapy in FGFR2 gene fusion-positive iCCA 20.4% objective…
ObsEva Provides Business Outlook for 2021
GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX:…
Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering
LAKE FOREST, Ill., Feb. 10, 2021 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the…
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM)…
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a…
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage…
Autolus Announces Pricing of Public Offering
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical…
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a…
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma…
Andy Hurley Named Agenus Chief Commercial Officer
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
Oncorus Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage…
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb….
Codiak Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a…